nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Brain oedema—Vandetanib—thyroid cancer	0.179	0.187	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Vandetanib—thyroid cancer	0.0354	0.0369	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Vandetanib—thyroid cancer	0.0316	0.033	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Vandetanib—thyroid cancer	0.0262	0.0273	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Vandetanib—thyroid cancer	0.0233	0.0244	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Vandetanib—thyroid cancer	0.0232	0.0242	CcSEcCtD
Cisatracurium Besylate—Convulsion—Vandetanib—thyroid cancer	0.0194	0.0202	CcSEcCtD
Cisatracurium Besylate—Hypertension—Vandetanib—thyroid cancer	0.0193	0.0202	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0189	0.0198	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Vandetanib—thyroid cancer	0.0179	0.0187	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Vandetanib—thyroid cancer	0.0178	0.0185	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Sorafenib—thyroid cancer	0.0171	0.0178	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Vandetanib—thyroid cancer	0.0163	0.017	CcSEcCtD
Cisatracurium Besylate—Flushing—Sorafenib—thyroid cancer	0.0161	0.0168	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Sorafenib—thyroid cancer	0.0157	0.0164	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Sorafenib—thyroid cancer	0.0157	0.0164	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Sorafenib—thyroid cancer	0.0156	0.0163	CcSEcCtD
Cisatracurium Besylate—Erythema—Sorafenib—thyroid cancer	0.0151	0.0158	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Epirubicin—thyroid cancer	0.0145	0.0152	CcSEcCtD
Cisatracurium Besylate—Angioedema—Sorafenib—thyroid cancer	0.0138	0.0144	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.0135	0.014	CcSEcCtD
Cisatracurium Besylate—Hypertension—Sorafenib—thyroid cancer	0.013	0.0136	CcSEcCtD
Cisatracurium Besylate—Pruritus—Vandetanib—thyroid cancer	0.0129	0.0135	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0128	0.0133	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Sorafenib—thyroid cancer	0.0123	0.0129	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Sorafenib—thyroid cancer	0.0121	0.0126	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Sorafenib—thyroid cancer	0.012	0.0125	CcSEcCtD
Cisatracurium Besylate—Rash—Vandetanib—thyroid cancer	0.0115	0.012	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Vandetanib—thyroid cancer	0.0115	0.012	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Sorafenib—thyroid cancer	0.011	0.0115	CcSEcCtD
Cisatracurium Besylate—Urticaria—Sorafenib—thyroid cancer	0.0098	0.0102	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.00958	0.00999	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Sorafenib—thyroid cancer	0.00909	0.00948	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.00887	0.00925	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Epirubicin—thyroid cancer	0.00882	0.0092	CcSEcCtD
Cisatracurium Besylate—Pruritus—Sorafenib—thyroid cancer	0.00873	0.0091	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Epirubicin—thyroid cancer	0.00818	0.00853	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Doxorubicin—thyroid cancer	0.00816	0.00851	CcSEcCtD
Cisatracurium Besylate—Rash—Sorafenib—thyroid cancer	0.00778	0.00811	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Sorafenib—thyroid cancer	0.00777	0.0081	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Doxorubicin—thyroid cancer	0.00757	0.00789	CcSEcCtD
Cisatracurium Besylate—CHRND—thyroid gland—thyroid cancer	0.0075	0.182	CbGeAlD
Cisatracurium Besylate—Bradycardia—Epirubicin—thyroid cancer	0.00653	0.00681	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Epirubicin—thyroid cancer	0.0063	0.00658	CcSEcCtD
Cisatracurium Besylate—CHRNA1—thyroid gland—thyroid cancer	0.00626	0.152	CbGeAlD
Cisatracurium Besylate—Bradycardia—Doxorubicin—thyroid cancer	0.00604	0.0063	CcSEcCtD
Cisatracurium Besylate—Flushing—Epirubicin—thyroid cancer	0.00595	0.00621	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00583	0.00608	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Epirubicin—thyroid cancer	0.00582	0.00607	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Epirubicin—thyroid cancer	0.00579	0.00604	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Epirubicin—thyroid cancer	0.00578	0.00603	CcSEcCtD
Cisatracurium Besylate—Erythema—Epirubicin—thyroid cancer	0.00558	0.00582	CcSEcCtD
Cisatracurium Besylate—CHRNA1—head—thyroid cancer	0.00555	0.135	CbGeAlD
Cisatracurium Besylate—Flushing—Doxorubicin—thyroid cancer	0.00551	0.00575	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Doxorubicin—thyroid cancer	0.00539	0.00562	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Doxorubicin—thyroid cancer	0.00536	0.00559	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00535	0.00558	CcSEcCtD
Cisatracurium Besylate—CHRNA2—thyroid gland—thyroid cancer	0.00519	0.126	CbGeAlD
Cisatracurium Besylate—Erythema—Doxorubicin—thyroid cancer	0.00517	0.00539	CcSEcCtD
Cisatracurium Besylate—Convulsion—Epirubicin—thyroid cancer	0.00484	0.00505	CcSEcCtD
Cisatracurium Besylate—CHRNB1—thyroid gland—thyroid cancer	0.00483	0.117	CbGeAlD
Cisatracurium Besylate—Hypertension—Epirubicin—thyroid cancer	0.00482	0.00503	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00472	0.00492	CcSEcCtD
Cisatracurium Besylate—CHRNA2—head—thyroid cancer	0.00461	0.112	CbGeAlD
Cisatracurium Besylate—Anaphylactic shock—Epirubicin—thyroid cancer	0.00456	0.00475	CcSEcCtD
Cisatracurium Besylate—Convulsion—Doxorubicin—thyroid cancer	0.00448	0.00467	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Epirubicin—thyroid cancer	0.00447	0.00466	CcSEcCtD
Cisatracurium Besylate—Hypertension—Doxorubicin—thyroid cancer	0.00446	0.00465	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Epirubicin—thyroid cancer	0.00445	0.00464	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Epirubicin—thyroid cancer	0.00443	0.00462	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00437	0.00456	CcSEcCtD
Cisatracurium Besylate—CHRNB1—head—thyroid cancer	0.00429	0.104	CbGeAlD
Cisatracurium Besylate—Hypotension—Epirubicin—thyroid cancer	0.00426	0.00444	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00422	0.0044	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Doxorubicin—thyroid cancer	0.00414	0.00431	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Doxorubicin—thyroid cancer	0.00412	0.00429	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Doxorubicin—thyroid cancer	0.0041	0.00427	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Epirubicin—thyroid cancer	0.00406	0.00424	CcSEcCtD
Cisatracurium Besylate—Hypotension—Doxorubicin—thyroid cancer	0.00394	0.00411	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Doxorubicin—thyroid cancer	0.00376	0.00392	CcSEcCtD
Cisatracurium Besylate—Urticaria—Epirubicin—thyroid cancer	0.00362	0.00378	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Epirubicin—thyroid cancer	0.00336	0.0035	CcSEcCtD
Cisatracurium Besylate—Urticaria—Doxorubicin—thyroid cancer	0.00335	0.00349	CcSEcCtD
Cisatracurium Besylate—Pruritus—Epirubicin—thyroid cancer	0.00322	0.00336	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Doxorubicin—thyroid cancer	0.00311	0.00324	CcSEcCtD
Cisatracurium Besylate—CHRNB1—lymph node—thyroid cancer	0.003	0.0728	CbGeAlD
Cisatracurium Besylate—Pruritus—Doxorubicin—thyroid cancer	0.00298	0.00311	CcSEcCtD
Cisatracurium Besylate—Rash—Epirubicin—thyroid cancer	0.00287	0.003	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Epirubicin—thyroid cancer	0.00287	0.00299	CcSEcCtD
Cisatracurium Besylate—Rash—Doxorubicin—thyroid cancer	0.00266	0.00277	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Doxorubicin—thyroid cancer	0.00266	0.00277	CcSEcCtD
